The partial virological response to Tenofovir monotherapy in naïve patients with chronic hepatitis B

2020 ◽  
pp. 1-12
Author(s):  
Habip Gedik ◽  
Muge Sonmezisik
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Partial Response ◽  
Combination Therapy ◽  
Chronic Hepatitis B ◽  
Antiviral Drug ◽  
Sustained Viral Response ◽  
Treatment Naïve ◽  
Tenofovir Alafenamide ◽  
Partial Virological Response

Abstract We report two treatment-naïve cases, a 26-year-old female patient and a 59-year-old male patient who were followed up for chronic hepatitis B (CHB) at the Department of Infectious Diseases and Clinical Microbiology. A partial response subsequent to 12 months of Tenofovir Disoproksil (TDF) monotherapy presumably due to an antiviral-drug resistance was noted. A sustained viral response with TDF (245 mg) or Tenofovir Alafenamide (TAF, 25 mg) + Entecavir (ETV, 1 mg) combination therapy was observed after failure with TDF monotherapy. A combination therapy with TDF (245 mg) or TAF (25 mg) +ETV (1 mg) is efficacious in naïve patients with a partial response to TDF monotherapy. Keywords: Chronic hepatitis B, Tenofovir, partial response, Entecavir, combination therapy

scholarly journals COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B

Diagnostics ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 491
Author(s):  
Thuy Thi Bich Phung ◽  
Son Van Chu ◽  
Son Thien Vu ◽  
Hanh Thi Pham ◽  
Hang Minh Nguyen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Single Point ◽  
Antiviral Drug ◽  
Multiple Point ◽  
Resistance Mutations ◽  
Hbv Genotypes ◽  
Treatment Naïve ◽  
Pcr Method

We investigated Nucleos(t)ide-analogue (NA)-resistance mutations (mt) in 142 treatment-naive children with Chronic Hepatitis B (CHB), using a sensitive co-amplification at lower denaturation temperature (COLD)-PCR with Sanger DNA sequencing. An NA resistance-associated mt in the hepatitis B virus (HBV) reverse transcriptase (RT) was found in 66.2% of the patients, with nonclassical mt contributing the most (64.8%). Significantly higher frequencies of Lamivudine (LMV) and Adefovir dipivoxil (ADF) resistance-associated mt were found in genotypes B and C, respectively (ORLMV/ADF: 1495.000; 95% CI: 89.800–24,889.032; p < 0.001). Single-point mt associated to LMV and ADF resistance were detected in 59.9% of the tested children with rtV207M (38.0%) and rtN238T (9.9%) being the most frequent. Multiple-point mt were found only in 8 cases (5.6%): 6 children carried double mt (rtV207M + rtL229V; rtV207M + rtI233V; rtV207I + rtV207M × 2 cases; rtV207M + rtS213T; rtN238A + rtS256G) relating to LMV or/and ADF resistance and 3 children carried triple mt (rtL180M + rtM204I + rtN238T; rtV207M + rtS213T + rtS256G) or quadruple mt (rtL180M + rtM204V + rtV207I/M) for LMV-ADF resistance and Entecavir-reduced susceptibility. Our data indicate that significantly higher frequencies of LMV and ADF-associated mutations were found in treatment-naïve children infected with HBV genotypes B and C, respectively. The developed COLD-PCR method and obtained data may contribute to the development of suitable treatments for children with CHB.

“COMPARATIVE EFFICACY OF ENTECAVIR AND TENOFOVIR ALAFENAMIDE IN TREATMENT OF CHRONIC HEPATITIS-B ”

2021 ◽  
pp. 14-16
Author(s):  
Navneet Kumar Dubey ◽  
Ganesh Narayan Jha ◽  
Debarshi Jana
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
P Value ◽  
Comparative Efficacy ◽  
B Virus ◽  
Treatment Naïve ◽  
Medical Intensive Care ◽  
Tenofovir Alafenamide ◽  
Patient Department

Aims:The Aim of study is to compare the efcacy of entecavir with tenofovir alafenamide in treatment of Chronic Hepatitis B patients. Materials and methods: It is a prospective cohort study to compare efcacy of ENTECAVIR and TAF in treatment of Chronic Hepatitis B. Study location was Out Patient Department(OPD), In Patient Department(IPD) and Medical Intensive care unit (MICU) of Dept. of Medicine of DMCH, Laheriasarai. Study duration was 12 months and total 50 individual was in this study. Result: 12% patients of Entecavir and 16% patients of TAF group were presented with HTN; while DM was observed in 4% patients of Entecavir and 8% patients of TAF group. Regarding co-morbidities we found no signicant difference between two groups (p value = >0.05). Hepatitis B virus DNAin the HBeAg positive group was approximately 2 log10 IU/mLhigher than in the HBeAg-negative group. Conclusion: Treatment with antiviral therapy, ETV or TAF, showed potent antiviral activity against HBV and the efcacy of both drugs was comparable.TAF and ETVshowed comparable efcacy and safety in treatment-naïve CHB patients.

Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B

2011 ◽  
Vol 16 (4) ◽  
pp. 469-477 ◽  
Author(s):  
Young Eun Chon ◽  
Seung Up Kim ◽  
Chun Kyon Lee ◽  
Jeong Heo ◽  
Ja Kyung Kim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Treatment Naïve ◽  
Partial Virological Response

Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B

2020 ◽  
Vol 40 (7) ◽  
pp. 1578-1589
Author(s):  
Eiichi Ogawa ◽  
Hideyuki Nomura ◽  
Makoto Nakamuta ◽  
Norihiro Furusyo ◽  
Toshimasa Koyanagi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Combination Therapy ◽  
Chronic Hepatitis B ◽  
Tenofovir Alafenamide

scholarly journals Impact of Tenofovir Alafenamide Vs. Entecavir on Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B

2021 ◽  
Author(s):  
Hye Won Lee ◽  
Young Youn Cho ◽  
Beom Kyung Kim ◽  
Hyein Lee ◽  
Jae Seung Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Teaching Hospitals ◽  
Decompensated Cirrhosis ◽  
Kaplan Meier ◽  
Treatment Naïve ◽  
Tenofovir Alafenamide

Abstract Background & aims: Whether entecavir (ETV) or tenofovir alafenamide (TAF) is better at preventing hepatocellular carcinoma (HCC) development among patients with chronic hepatitis B (CHB) remains unclear. The present study was conducted to explore the ability of these two antivirals to prevent HCC.Methods: From 2012 to 2019, treatment-naïve CHB patients undergoing ETV or TAF therapy were recruited at three academic teaching hospitals. The TAF group comprised patients starting TAF as first-line antiviral and those switching antivirals from tenofovir disoproxil fumarate to TAF. Patients with decompensated cirrhosis or HCC at enrollment were excluded from the analysis. Cumulative probabilities of HCC were assessed using the Kaplan-Meier method.Results: In total, 1,810 patients (1,525 and 286 in ETV and TAF groups, respectively) were recruited. The annual HCC incidence was statistically not different between the ETV and TAF groups (1.67 vs. 1.19 per 100 person-years, respectively) with an adjusted hazard ratio (HR) of 0.681 (p=0.255), as determined by multivariate analysis. Male, hypertension, liver cirrhosis, FIB-4 index, and albumin were independent prognostic factors for HCC development. Propensity score-matched and inverse probability of treatment weighting analyses yielded similar results, with non-statistically different HCC incidence between the ETV and TAF groups (1.07 vs. 1.19 per 100 person-years (HR=0.973; p=0.953) and 1.67 vs. 1.89 per 100 person-years, respectively (HR=0.949; p=0.743).Conclusions: These findings suggest that ETV- and TAF-treated CHB patients have similar risk of developing HCC. Further studies with the larger sample size and longer follow-up are needed to validate these results.

scholarly journals Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response

2015 ◽  
Vol 59 (9) ◽  
pp. 5348-5356 ◽  
Author(s):  
Hyun Woong Lee ◽  
Jae-Cheol Kwon ◽  
In Soo Oh ◽  
Hye Young Chang ◽  
Young Joo Cha ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Hbeag Seroconversion ◽  
Hbv Dna ◽  
Duration Of Treatment ◽  
Genotypic Resistance ◽  
Treatment Naïve ◽  
Partial Virological Response

ABSTRACTThe aims of this study were to investigate the efficacy of prolonged entecavir (ETV) therapy in treatment-naive chronic hepatitis B (CHB) patients and to determine whether continuous ETV therapy is feasible to achieve HBeAg seroconversion, particularly in patients with partial virological response (PVR). A total of 142 treatment-naive patients with CHB were enrolled. The mean duration of treatment was 65 (range, 26 to 90) months, and 86 patients (60.6%) were HBeAg positive. PVR was defined as detectable hepatitis B virus (HBV) DNA (>116 copies/ml) at year 1. The cumulative incidence of virological response (VR) increased from 54.9% at year 1 to 98.2% at year 7. HBeAg positivity (odds ratio [OR], 4.146;P= 0.001) and initial alanine aminotransferase (ALT) (OR, 0.997;P= 0.004) were independent risk factors for PVR. Among the 64 patients with PVR, 47 patients (73.4%) achieved VR within 4 years after prolonged ETV therapy without treatment adaptation. Three patients (2.1%) experienced virological breakthrough and HBV variants with genotypic resistance. The cumulative rate of HBeAg seroconversion was significantly higher in the patients with VR than in the patients with PVR (P= 0.018). None of the PVR patients with HBV DNA at ≥5,000 copies/ml at year 1 ever experienced HBeAg seroconversion. Multivariate analysis identified VR at year 1 as the only determinant of HBeAg seroconversion (hazard ratio [HR], 3.009;P= 0.010). In conclusion, although there were patients with PVR, prolonged ETV therapy showed excellent VR, with only 2.1% emergence of viral resistance during a 7-year follow-up. However, to achieve HBeAg seroconversion, drug modification is needed for HBeAg-positive patients with PVR (especially those with HBV DNA at ≥5,000 copies/ml at year 1).

scholarly journals Beneficial Effects of Bushen Formula Combined with Enticavir on Chronic Hepatitis B Patients with Suboptimal Response to Enticavir by Regulating B-Cell Differentiation

2018 ◽  
Vol 48 (2) ◽  
pp. 633-643 ◽  
Author(s):  
Man Li ◽  
Zhen-Hua Zhou ◽  
Ting Bao ◽  
Xin Zhang ◽  
Xiao-Jun Zhu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
B Cells ◽  
Chinese Medicine ◽  
Hepatitis B ◽  
Combination Therapy ◽  
B Cell ◽  
Chronic Hepatitis B ◽  
Healthy Controls ◽  
Treatment Naïve ◽  
Symptom Complex

Background/Aims: To investigate the clinical effects of the combination therapy with Bushen Formula (BSF) plus enticavir (ETV) on chronic hepatitis B (CHB) patients with suboptimal response to ETV and explore the regulatory mechanisms of BSF on B cells-mediated humoral immunity. Methods: Sixty-four HBeAg-positive CHB patients with suboptimal response to ETV were enrolled, and were randomly assigned into control group (C-Group, placebo combined with ETV for 12 months) or treatment group (T-Group, BSF combined with ETV for 12 months). Serum samples from 57 treatment-naïve CHB patients and 15 healthy controls were collected. Serum HBV DNA levels were evaluated by real-time PCR. Characteristics of peripheral blood B-cell subtypes were analyzed by flow cytometry. Serum HBV markers and B cell-activating factor (BAFF) levels were detected by ELISA. Chinese medicine symptom complex score was evaluated and recorded. Results: After treatment, the rates of patients with a reduction of HBsAg > 0.5 log10 IU/ml or 1.0 log10 IU/ml and the rates of HBeAg clearance in T-Group were all higher than those in C-group, with no significant intergroup difference. Only in T-Group, Chinese medicine symptom complex score and the frequency of total B cells were significantly decreased, and the frequencies of Bm1, CD24+CD27-switched B cells and plasma cells were markedly increased after treatment compared with those before treatment. Compared with healthy controls, serum BAFF levels in treatment-naïve CHB patients were increased, and there was a significant positive correlation between serum BAFF and HBsAg levels. However, serum BAFF levels did not differ after treatment in T-Group and C-Group. Conclusions: The combination therapy with BSF plus ETV promotes the reduction of HBsAg level and the clearance of HBeAg in CHB patients with partial response to ETV through regulating the differentiation of B-cell subsets.

Sign in / Sign up

Export Citation Format

Share Document